Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks

Stock Track

Jun 01

SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.

The movement appears linked to the company being highlighted as a key healthcare pick in a prominent June investment strategy report. The report details SKB BIO's focus on ADC drug development and its landmark partnership with Merck & Co. for its pipeline asset, sac-TMT. Positive clinical data and the initiation of larger-than-expected global Phase III trials by Merck have bolstered market confidence in the drug's potential.

Analysts note that as Chinese clinical data continues to accumulate, sac-TMT's Best-in-Class profile is becoming clearer. With Merck rapidly advancing global registrational studies, key data readouts are approaching, supporting an estimated peak global sales potential of $15 billion for the asset. The company is expected to achieve profitability in 2027, with the clinical value of sac-TMT likely to increase significantly in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1140143804"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140143804\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140143804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140143804","market":"us","top_or_hot":-1,"title":"Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks","media":"Stock Track","content":"<p>SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.</p><p>The movement appears linked to the company being highlighted as a key healthcare pick in a prominent June investment strategy report. The report details SKB BIO's focus on ADC drug development and its landmark partnership with Merck & Co. for its pipeline asset, sac-TMT. Positive clinical data and the initiation of larger-than-expected global Phase III trials by Merck have bolstered market confidence in the drug's potential.</p><p>Analysts note that as Chinese clinical data continues to accumulate, sac-TMT's Best-in-Class profile is becoming clearer. With Merck rapidly advancing global registrational studies, key data readouts are approaching, supporting an estimated peak global sales potential of $15 billion for the asset. The company is expected to achieve profitability in 2027, with the clinical value of sac-TMT likely to increase significantly in 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.</p><p>The movement appears linked to the company being highlighted as a key healthcare pick in a prominent June investment strategy report. The report details SKB BIO's focus on ADC drug development and its landmark partnership with Merck & Co. for its pipeline asset, sac-TMT. Positive clinical data and the initiation of larger-than-expected global Phase III trials by Merck have bolstered market confidence in the drug's potential.</p><p>Analysts note that as Chinese clinical data continues to accumulate, sac-TMT's Best-in-Class profile is becoming clearer. With Merck rapidly advancing global registrational studies, key data readouts are approaching, supporting an estimated peak global sales potential of $15 billion for the asset. The company is expected to achieve profitability in 2027, with the clinical value of sac-TMT likely to increase significantly in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1140143804","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140143804","pubTimestamp":1780277610,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.The movement appears linked to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"个股追踪|SKB BIO开盘飙升5.67%，因药物管线进展积极并被纳入首选个股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"SKB BIO (stock code: 06990) saw its stock price soar 5.67% at the market open on Monday, reflecting strong investor interest in the innovative biopharma company.The movement appears linked to the company being highlighted as a key healthcare pick in a prominent June investment strategy report. The report details SKB BIO's focus on ADC drug development and its landmark partnership with Merck & Co. for its pipeline asset, sac-TMT. Positive clinical data and the initiation of larger-than-expected global Phase III trials by Merck have bolstered market confidence in the drug's potential.Analysts note that as Chinese clinical data continues to accumulate, sac-TMT's Best-in-Class profile is becoming clearer. With Merck rapidly advancing global registrational studies, key data readouts are approaching, supporting an estimated peak global sales potential of $15 billion for the asset. The company is expected to achieve profitability in 2027, with the clinical value of sac-TMT likely to increase significantly in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}